Newsroom

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Media Center

Press Release

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Read Now

Press Release

Scribe Therapeutics to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

March 31, 2023

Read Now

Media

Industry appetite for natural killer cells intensifies

February 15, 2023

Nature Biotechnology

Read Now

Press Release

Industry appetite for natural killer cells intensifies

February 15, 2023

Nature Biotechnology

Read Now

Media

Economic Forecast 2023

January 6, 2023

San Francisco Business Times

Read Now

Press Release

Economic Forecast 2023

January 6, 2023

San Francisco Business Times

Read Now

Press Release

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Read Now

Press Release

Scribe Therapeutics to Participate in Four Upcoming Conferences

November 17, 2022

Read Now

Media

Building a biotech in a downturn: 3 lessons from VCs and startup CEOs

November 3, 2022

Biopharma Dive

Read Now

Press Release

Building a biotech in a downturn: 3 lessons from VCs and startup CEOs

November 3, 2022

Biopharma Dive

Read Now

Media

Deals In Depth: September 2022

October 18, 2022

In Vivo

Read Now

Press Release

Deals In Depth: September 2022

October 18, 2022

In Vivo

Read Now

Media

Scribe’s Genetic Editing Aims to Prevent Heart Attacks

July 27, 2026

Barron's

Read Now

Media

Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds

July 24, 2026

Fierce Biotech

Read Now

Media

Eli Lilly-Backed Scribe Therapeutics Soars 44% After IPO

July 24, 2026

Bloomberg News

Read Now

Media

Scribe Bets on a New Era of Gene Editing

July 24, 2026

Bloomberg Tech

Read Now

Media

Scribe prices upsized IPO before producing human efficacy data

July 24, 2026

Axios

Read Now

Media

CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO

July 24, 2026

MedCity News

Read Now

Press release

Scribe Therapeutics to Unveil Latest Preclinical Data on Proprietary CRISPR Epigenetic Silencing Technology for LDL-C Lowering at the 2025 EAS Congress

April 23, 2025

Read Now

Press release

Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

March 7, 2025

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now

Press release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now

Press release

Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Read Now

Press release

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Read Now

Publications

Publication

Sequential Proofreading Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

August 31, 2026

bioRxiv

Read Now

Publication

Engineered Allosteric Control Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

January 14, 2026

bioRxiv

Read Now

Publication

Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging

May 18, 2025

Journal of Controlled Release

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now